Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Raludotatug deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with CDH6 expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab Raludotatug […]
Weekly Digest – September 2025 Weekly Digest – September 2025 16 September 2025: FDA grants Fast Track Designation to Corbus Pharmaceuticals Nectin-4 targeting ADC CRB-701 in head and neck squamous cell carcinoma Corbus Pharmaceuticals announced that the FDA granted Fast […]
Weekly Digest – September 2025 Weekly Digest – September 2025 17 September 2025: Hengrui Medicine has received its marketing authorization application for a new indication for its Ruikang trastuzumab injection and has been included in the priority review process Hengrui […]
